Beam Therapeutics Faces Setback in CRISPR Trial Amid Financial Updates
TL;DR Summary
A patient with sickle cell disease died from respiratory failure during a clinical trial of Beam Therapeutics' CRISPR-based treatment, BEAM-101. The death, attributed to chemotherapy preparation for the gene editing therapy, raises concerns despite early promising results. This was the first death among six participants in the trial.
- Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment STAT
- Beam Therapeutics's Earnings: A Preview Benzinga
- Beam Therapeutics to Present Data Across Hematology GlobeNewswire
- Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates GuruFocus.com
- Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting TipRanks
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
1 min
vs 2 min read
Condensed
79%
233 → 48 words
Want the full story? Read the original article
Read on STAT